Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9432293 | 0.74 | ALDH1A1 (0.38) | ALDH1A1CYP2D6ALOX15HTTPOLB | |
| SCHEMBL10894325 | 0.74 | ALDH1A1 (0.38) | ALDH1A1CYP2D6ALOX15HTTPOLB | |
| SCHEMBL6947992 | 0.74 | ESR2 (0.36) | KDM4ESETD7HRH3 | |
| SCHEMBL10891992 | 0.74 | ALDH1A1 (0.38) | ALDH1A1CYP2D6ALOX15HTTPOLB | |
| SCHEMBL5516168 | 0.73 | ALDH1A1 (0.33) | ALDH1A1CYP2D6ALOX15 | |
| SCHEMBL25404223 | 0.72 | ALDH1A1 (0.36) | ALDH1A1CYP2D6ALOX15 | |
| SCHEMBL8325073 | 0.72 | CYP3A4 (0.37) | KDM4EALDH1A1MAPTADORA1RAD52 | |
| SCHEMBL12972268 | 0.72 | HRH3 (0.36) | SETD7HRH3 | |
| SCHEMBL24131684 | 0.70 | HRH3 (0.35) | HRH3 | |
| SCHEMBL6947677 | 0.70 | NOS1 (0.35) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3815685-A2 | COMPOUND COMPRISING A MAO TARGETING/SEEKER MOIETY FOR TREATING HUMAN GLIOMAS | The Methodist Hospital Research Institute (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10555936-B2 | Chemotherapeutic compositions and methods for treating human gliomas | THE METHODIST HOSPITAL (US) | 2020-02-11 | — | — | US | disclosed |
| EP-2804604-A1 | COMPOUND COMPRISING A MAO TARGETING/ SEEKER MOIETY FOR TREATING HUMAN GLIOMAS | The Methodist Hospital Research Institute (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20140323513-A1 | Chemotherapeutic Compositions and Methods for Treating Human Gliomas | THE METHODIST HOSPITAL | 2014-10-30 | — | — | US | disclosed |
| WO-2013151584-A1 | COMPOUND COMPRISING A MAO TARGETING/ SEEKER MOIETY FOR TREATING HUMAN GLIOMAS | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10555936-B2 | Chemotherapeutic compositions and methods for treating human gliomas | TK2, IDH2, COX5B | KDM4E 1789/4885ALDH1A1 500/4885MAPT 1201/4885 |
| US-20140323513-A1 | Chemotherapeutic Compositions and Methods for Treating Human Gliomas | TK2, IDH2, COX5B | KDM4E 1789/4885ALDH1A1 500/4885MAPT 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.